Referred to the House Committee on Energy and Commerce.
This bill amends section 351(k) of the Public Health Service Act to change how a biosimilar biological product can be determined to be interchangeable with its reference product. Under the bill, a biosimilar licensed on or after a 60-day transition date would generally be "deemed" interchangeable upon licensure except when a previously issued "first interchangeable" exclusivity period for a competing product (in effect before enactment) blocks immediate deemed interchangeability until that exclusivity expires.
Whether automatic "deemed" interchangeability materially lowers scientific or safety standards (progressives emphasize risk; conservative downplays it).
Relative to its intended legislative type, this bill clearly targets substantive change by altering statutory rules for interchangeability of biosimilar products and supplies specific legal mechanisms (statutory text changes, transition date, exclusivity preservation) plus administrative deadlines for revised guidances.
This bill amends section 351(k) of the Public Health Service Act to change how a biosimilar biological product can be determined to be interchangeable with its reference product.
Under the bill, a biosimilar licensed on or after a 60-day transition date would generally be "deemed" interchangeable upon licensure except when a previously issued "first interchangeable" exclusivity period for a competing product (in effect before enactment) blocks immediate deemed interchangeability until that exclusivity expires.
The bill preserves any unexpired first interchangeable exclusivity periods that existed before enactment, requires the Secretary of HHS/FDA to update relevant guidances within specified timelines (generally 18 months), and includes conforming amendments to related statutory provisions.
On content alone, the bill is a narrowly tailored regulatory change that could appeal to constituencies favoring lower drug costs and streamlined approvals and therefore has some prospects. However, because it materially alters the interchangeability determination for biologics (with consequences for a large and well‑resourced industry), it is likely to provoke concentrated opposition and require negotiation. The absence of built‑in compromise mechanisms beyond limited transition protections and the potential for state‑level friction and litigation reduce its near‑term likelihood of becoming law.
Relative to its intended legislative type, this bill clearly targets substantive change by altering statutory rules for interchangeability of biosimilar products and supplies specific legal mechanisms (statutory text changes, transition date, exclusivity preservation) plus administrative deadlines for revised guidances.
Whether automatic "deemed" interchangeability materially lowers scientific or safety standards (progressives emphasize risk; conservative downplays it).
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether automatic "deemed" interchangeability materially lowers scientific or safety standards (progressives emphasize risk; conservative downplays it).
A mainstream liberal would see potential public-interest advantages in increasing biosimilar competition (lowering drug costs, expanding access), but would be wary that the bill effectively removes an additional regulatory step (separate interchangeability determination) that has in the past required clinical switching data.
They would note the bill's explicit language preserving the biosimilarity licensure standard, but remain concerned that the practical effect of automatic "deemed" interchangeability could reduce evidentiary scrutiny or lead to substitution without adequate patient/provider safeguards.
They would likely condition support on stronger implementation protections, robust post‑market monitoring, and state-level substitution protections to protect vulnerable patients.
A moderate would view the bill as a pragmatic effort to reduce regulatory friction and encourage competition in biologics markets, but would watch for unintended consequences and implementation details.
They would appreciate the bill's preservation of preexisting exclusivity and the explicit non-alteration clause for the biosimilarity standard, while wanting clear, timely FDA guidance and monitoring to avoid lowering scientific standards in practice.
Overall, a centrist would lean in favor if the FDA produces clear guidance and if there are safeguards on safety monitoring and clear communications to states and providers.
A mainstream conservative would likely view this bill positively as reducing regulatory barriers, cutting "red tape," and facilitating competition in the biopharmaceutical market that can lower prices and expand consumer choice.
They would welcome the automatic deemed interchangeability mechanism as a pro-competition reform and point to the bill's preservation of prior exclusivity and explicit language that it does not change the biosimilarity licensure standard.
Concerns would be limited, focused primarily on ensuring the FDA implements the changes promptly and that existing intellectual property/exclusivity rights are respected.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a narrowly tailored regulatory change that could appeal to constituencies favoring lower drug costs and streamlined approvals and therefore has some prospects. However, because it materially alters the interchangeability determination for biologics (with consequences for a large and well‑resourced industry), it is likely to provoke concentrated opposition and require negotiation. The absence of built‑in compromise mechanisms beyond limited transition protections and the potential for state‑level friction and litigation reduce its near‑term likelihood of becoming law.
The bill has not accumulated any surfaced votes yet.
Whether automatic "deemed" interchangeability materially lowers scientific or safety standards (progressives emphasize risk; conservative d…
On content alone, the bill is a narrowly tailored regulatory change that could appeal to constituencies favoring lower drug costs and strea…
Relative to its intended legislative type, this bill clearly targets substantive change by altering statutory rules for interchangeability of biosimilar products and supplies specific legal mechanisms (statutory text ch…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.